A study reporting on DiscGenics’ cell therapy phase 1 and 2 study has been selected as one of three of the best and most influential articles published in the International Journal of Spine Surgery in ...

DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the ...